Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NYSE:ALB
NYSE:ALBChemicals

Albemarle (ALB): Ongoing Losses Challenge Bullish Turnaround Narratives Despite Strong Profitability Forecasts

Albemarle (ALB) remains unprofitable, with reported losses having increased at an average rate of 22.5% per year across the last five years and no improvement shown in net profit margins in its most recent filing. Despite these challenges, the company’s earnings are forecast to rebound sharply at a predicted 66.75% annual growth rate, with profitability expected within three years. Revenue is projected to climb by 8.5% per year, which is slower than the US market average of 10.4%. See our...
NasdaqGS:ARAY
NasdaqGS:ARAYMedical Equipment

Accuray (ARAY) Losses Increase 28.3% Annually, Challenging Turnaround Narrative Despite Profitability Forecast

Accuray (ARAY) has remained unprofitable, with losses deepening at an annual rate of 28.3% over the past five years. While revenue is projected to grow at 4.4% per year, which is slower than the broader US market’s 10.4% average, earnings are expected to rise sharply at 116.63% per year. This sets the company on course to become profitable within three years. With a Price-To-Sales Ratio of 0.3x and the current share price trading below the estimated fair value of $5.17, investors are keeping...
TSX:IFC
TSX:IFCInsurance

Intact Financial (TSX:IFC) Margin Expansion Reinforces Bullish Narrative Despite Forecast Earnings Decline

Intact Financial (TSX:IFC) posted a 44.4% jump in earnings over the past year, with profit margins rising to 10% from 6.8% twelve months ago. While the company averaged earnings growth of 9.2% per year over the past five years, revenues and earnings are now expected to decline by 3.1% and 1.8% per year over the next three years. This leaves investors weighing robust historical results against a more cautious outlook. See our full analysis for Intact Financial. Now, let's see how these...
NasdaqCM:OCGN
NasdaqCM:OCGNBiotechs

Ocugen (OCGN): Valuation Pressures Challenge Bullish Narrative as Profitability Remains Elusive

Ocugen (OCGN) is projected to deliver rapid revenue growth of 75.3% per year, with earnings expected to rise 77.45% annually, both far exceeding the broader US market estimates. The company remains unprofitable, having posted a 3.8% average annual increase in losses over the past five years, and its share price currently trades at $1.38. Investors will weigh these aggressive growth forecasts against Ocugen’s continued net margin struggles and premium valuation, especially given a...